[Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytoses].
15 patients with myeloproliferative diseases and thrombocythaemia (7 Polycythaemia vera, 5 essential thrombocythaemia, 3 chronic myelogenous leukaemia) were assigned to a therapy with recombinant interferon (recombinant IFN-alpha-2C) in a prospective, controlled trial. Under therapy all patients showed a significant decrease in thrombocyte values. 51% of the patients revealed thrombocyte values within the normal range after 3 months of IFN therapy. Noted side effects of IFN therapy were dose-dependent and clinically well tolerated by the patients.
D000368:Aged; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D004906:Erythrocyte Count / Q000187:drug effects; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D007951:Leukemia, Myeloid / Q000188:drug therapy; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000188:drug therapy*; D010976:Platelet Count / Q000187:drug effects; D011087:Polycythemia Vera / Q000188:drug therapy; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000627:therapeutic use*; D013920:Thrombocythemia, Essential / Q000188:drug therapy; D013922:Thrombocytosis / Q000188:drug therapy*
D007370:Interferon Type I; D011994:Recombinant Proteins
Therapie mit Interferon (rekombinantes IFN-alpha-2C) bei myeloproliferativen Erkrankungen mit exzessiven Thrombozytosen.